Biogen Idec has added another bow to its multiple sclerosis quiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of the MS market.
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.
Biogen Idec's multibillion-selling multiple sclerosis drug Tecfidera is grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its own product.
Denmark's Forward Pharma has a plan to contend with Biogen Idec and its multibillion-selling multiple sclerosis drug Tecfidera, eyeing $200 million in a U.S. IPO to bankroll its offensive.
Biogen Idec's multiple sclerosis blockbuster Tecfidera for a second time has hit a roadblock in its effort to replicate in Europe the kind of runaway success it has had in the U.S. Germany's price watchdog IQWIG says it has found "no additional benefit" for the treatment compared to existing options, a preliminary decision that could deny it premium pricing there.
For Biogen Idec's second quarter, multiple sclerosis star Tecfidera blew analysts' estimates out of the water, as it's been wont to do. But it wasn't Tecfidera alone that helped the Massachusetts biotech trounce sales estimates by about $250 million.
What's better than beating sales estimates with a new drug? Blowing those estimates out of the water. Biogen Idec can celebrate that today, thanks to $700 million in quarterly Tecfidera sales.
Alkermes has its sights set on Biogen Idec's blockbuster multiple sclerosis treatment, advancing a me-better candidate of its own into Phase I study.
Biogen Idec's multiple sclerosis pill Tecfidera has been steamrolling since it hit the U.S. market last April. And now, it's poised to pad global sales with a victory in the U.K., whose cost watchdog has given it the OK in final guidance after flip-flopping on a February decision not to endorse the drug.
Back in April, Biogen Idec stirred up the hemophilia B market by pricing its long-acting newcomer Alprolix on par with older meds. Now, it's doing the same with April approval Eloctate, another long-lasting drug--but in a hemophilia A market where the stakes are much, much higher.